To meet the clinical need for a therapeutic agent for treatment of PCa, some promising urea-based candidates have been investigated, [177Lu]Lu-PSMA-617 and [177Lu]Lu-PSMA-I&T [8,9]. This evidence concerns the gene FOLH1 and posterior cortical atrophy.